Table 2.

Median and 5-year overall survival by treatment, timing of treatment and stage

Timing	Margin status	Median survival (months)	Five-year overall survival (%), 95% CI	HR	P value	Margin negative resection rate (%), P value
NAT	Neg	23.2	26.5 (24.7 to 28.4)	0.28	<0.001	88, <0.001
NAT	Pos	17.6	14.5 (10.97 to 18.5)	0.43	<0.001
AT	Neg	21.5	22.7 (21.7 to 23.6)	0.32	<0.001	81, <0.001
AT	Pos	16.8	11.9 (10.5 to 13.5)	0.47	<0.001
Surg	Neg	13.1	16.1 (15 to 17.2)	0.50	<0.001	81, <0.001
Surg	Pos	6.8	6.7 (5.2 to 8.4)	0.96	0.25
No surgery	N/A	10.3	5.3 (4.98 to 5.5)	Reference	Reference	N/A

Timing/ stage	Margin status	Median urvival (monthss)	Five-year overall survival (%), 95% CI	P value	Margin negative resection rate (%), P value
Stage IIA
NAT	Neg	23.6	28.2 (25.2 to 31.0)	<0.001	88, <0.001
NAT	Pos	16.9	14.3 (9.3 to 20.4)	Reference
AT	Neg	22.3	25.1 (23.8 to 26.3)	<0.001	83, reference
AT	Pos	18.0	13.8 (11.8 to 15.9)	0.56	83, reference
Surg	Neg	14.8	18.2 (16.7 to 20)	0.84
Surg	Pos	7.7	8.5 (6.3 to 11.1)	<0.001
NoSurg		10.4	5.6 (5.3 to 6.5)	<0.001
Stage IIB
NAT	Neg	22.4	25.4 (22.2 to 28.8)	<0.001	89, <0.001
NAT	Pos	17.4	13.3 (7.3 to 21.2)	Reference
AT	Neg	20.3	18.7 (17.1 to 20.3)	0.03	83, reference
AT	Pos	16.5	11.3 (8.8 to 14.2)	0.61	83, reference
Surg	Neg	11.6	13.7 (11.1 to 15.6)	0.03
Surg	Pos	6.8	5.2 (3.1 to 8.2)	<0.001
NoSurg		9.7	5.5 (4.9 to 6.2)	<0.001
Stage III
NAT	Neg	23.4	24.4 (20.7 to 28.3)	0.015	85, <0.001
NAT	Pos	19.8	16.0 (9.4 to 24)	Reference	59, reference
AT	Neg	18.4	19.2 (15.2 to 23.6)	1.00
AT	Pos	13.6	5.6 (3.3 to 8.9)	<0.001	59, reference
Surg	Neg	8.2	7.7 (4.9 to 11.3)	<0.001
Surg	Pos	6.1	3.5 (1.4 to 7.2)	<0.001
NoSurg		10.4	4.9 (4.6 to 5.3)	<0.001

AT, adjuvant therapy; NAT, neoadjuvant therapy; Neg, negative; Pos, positive; Surg, surgery.